Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis
Rupali Fuldeore, Adaeze Q. Amaefule, Gergana Georgieva, Tomomi Kimura, Baoguo Jiang, Kenneth H. Yu · 2026
Read Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis by Rupali Fuldeore, Adaeze Q. Amaefule, Gergana Georgieva, Tomomi Kimura, Baoguo Jiang, Kenneth H. Yu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13374745.txt.
Description
Rupali Fuldeore and colleagues tallied what metastatic pancreatic cancer costs the US health system, in a 2026 claims analysis. The team drew adult patients diagnosed between January 2020 and December 2022 from the Merative MarketScan database, covering commercial and Medicare plans. Visits and costs were counted per person per month for a year after diagnosis.
Among 2318 patients, mean monthly costs reached 34,215 dollars commercially and 15,158 dollars under Medicare. A quarter of commercial patients and 43.2 percent of Medicare patients received no first-line treatment within 90 days. The figures expose both the heavy price of advanced pancreatic cancer and a treatment gap for older patients.
Catalog record
| CREATOR | Rupali Fuldeore, Adaeze Q. Amaefule, Gergana Georgieva, Tomomi Kimura, Baoguo Jiang, Kenneth H. Yu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |